Costimulation of CD4+ T cells via CD28 modulates human immunodeficiency virus type 1 infection and replication in

M D Smithgall1, J G Wong, P S Linsley

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA.

Insights

T-cell activation via CD28 costimulation significantly boosts human immunodeficiency virus type 1 (HIV-1) replication. Blocking the CD28 pathway with CTLA4Ig inhibits HIV-1 replication, suggesting a therapeutic target.

Area of Science:

  • Immunology
  • Virology
  • Molecular Biology

Background:

  • TCR-CD3 stimulation of HIV-1-infected cells induces virus production.
  • Optimal T-cell activation requires both primary (TCR-CD3) and secondary (costimulatory) signals.
  • The role of CD28 costimulation in HIV-1 replication requires further investigation.

Purpose of the Study:

  • To investigate the role of CD28 costimulation in HIV-1 replication.
  • To determine if CD28 ligation enhances HIV-1 production or de novo infection.
  • To assess the impact of interfering with the CD28 costimulatory pathway on HIV-1 replication.

Main Methods:

  • Stimulation of peripheral blood mononuclear cells (PBMCs) from HIV-1-infected donors via TCR-CD3 and CD28.
  • Coculture of PBMCs with Chinese hamster ovary (CHO) cell lines expressing CD28 counterreceptors (B7-1, B7-2).
  • Assessment of HIV-1 replication and de novo infection.
  • Interference with CD28-counterreceptor interaction using CTLA4Ig.
  • Evaluation of IL-2 levels and cell proliferation.

Main Results:

  • CD28 ligation, combined with CD3 stimulation, significantly increased HIV-1 replication compared to CD3 stimulation alone.
  • CD28 ligation augmented de novo infection of HIV-1-seronegative PBMCs.
  • Increased virus replication was not solely due to elevated IL-2 levels.
  • CTLA4Ig effectively inhibited HIV-1 replication by blocking CD28-counterreceptor interactions.
  • High concentrations of CTLA4Ig also reduced T-cell proliferation.

Conclusions:

  • CD28 costimulation plays a critical role in enhancing HIV-1 replication.
  • Interfering with the CD28 costimulatory pathway holds potential for modifying HIV-1 infection.
  • Targeting the CD28 pathway represents a promising therapeutic strategy for HIV-1.